Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 5/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409038 | 0.85 | SYK (0.71) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL13791083 | 0.85 | SYK (0.59) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL4573352 | 0.84 | SYK (0.58) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL212928 | 0.84 | HTR2C (0.59) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL13803105 | 0.82 | SYK (0.55) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL4056455 | 0.82 | ALDH1A1 (0.59) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL27317490 | 0.82 | SMN1; SMN2 (0.57) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL5319656 | 0.81 | KDM4E (0.70) | SYKTSHRPOLBCYP2D6KDM4E | |
| SCHEMBL11951009 | 0.81 | SYK (0.54) | SYKHTR2CHTR2BHTR2ATSHR | |
| SCHEMBL19125158 | 0.81 | SYK (0.54) | SYKHTR2CHTR2BHTR2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | SYK 4519/4885HTR2C 98/4885HTR2B 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.